Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Fibrogen Inc CS (NQ: FGEN )

0.3890 +0.0014 (+0.36%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 27, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Fibrogen Inc CS

< Previous 1 2 3 4 5 6 7 Next >
Why Are Chip Stocks Up Today?
Chip stocks are up today and investors wondering why will find all of the news explaining the rally in the sector on Wednesday. 
Via InvestorPlace
FibroGen Layoffs 2024: What to Know About the Latest FGEN Job Cuts
FibroGen layoffs are in the news Wednesday after the biopharmaceutical company announced plans to cut jobs after failed clinical trials. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
Why is Macrogenics (MGNX) Stock Down 28% Today?
Macrogenics stock is down on Wednesday after MGNX investors learned that the company is discontinuing a Phase 2 clinical trial. 
Via InvestorPlace
Why Is FibroGen (FGEN) Stock Down 44% Today?
FibroGen stock is down on Wednesday as FGEN investors react to the company's failed clinical trials for its pancreatic cancer treatment. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to dive into the biggest pre-market stock movers for Wednesday as we check out all of the hottest news happening this morning! 
Via InvestorPlace
Earnings Scheduled For November 12, 2024
Via Benzinga
Earnings Outlook For FibroGen
Via Benzinga
FGEN Stock Earnings: FibroGen Beats EPS, Beats Revenue for Q2 2024
FGEN stock results show that FibroGen beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Nasdaq Surges Over 3%; Powell Industries Shares Spike Higher
Via Benzinga
Dow Jumps Over 200 Points; Kraft Heinz Shares Gain After Q2 Earnings
Via Benzinga
Topics Stocks
Exposures US Equities
One Year, Five Trial Failures: FibroGen Terminates Pancreatic Cancer Treatment Program
FibroGen reports topline results from late-stage trials of pamrevlumab for pancreatic cancer, failing to meet the primary endpoint of overall survival. 
Via Benzinga
Ground Cinnamon Recalls: What to Know as FDA Issues Alert Over Lead Levels
New ground cinnamon recalls are in effect as the FDA warns consumers about increased lead levels in some of these products. 
Via InvestorPlace
Topics Product Recall
Exposures Legal Product Safety
Why AMD Shares Are Trading Higher By Over 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
What's Going On With FibroGen Stock Tuesday?
FibroGen Inc (NASDAQ:FGEN) shares are trading higher Tuesday morning after the company said the FDA cleared its Investigational New Drug (IND) of FG-3165. FibroGen also announced a new clinical trial... 
Via Benzinga
Exposures Product Safety
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start Tuesday with a breakdown of the biggest pre-market stock movers traders will want to know about this morning! 
Via InvestorPlace
Why HealthEquity Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket
Via Benzinga
FibroGen Stock Is Surging After The Bell: What's Going On?
FibroGen shares are moving higher in Monday's after-hours session after the company announced the FDA cleared its Investigational New Drug (IND) FG-3165. The company also announced a new clinical trial... 
Via Benzinga
Exposures Product Safety
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
7 Penny Biotech Stocks to Triple Your Investment
Biotech penny stocks offer the chance to triple your investments and require an appetite for risk in order to capture returns. 
Via InvestorPlace
Why Beyond Shares Are Trading Lower By Over 20%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
FibroGen Shares Climb On Strong Q1 Sales
FibroGen reported quarterly losses of 33 cents per share which missed the analyst consensus estimate of $(0.31) and represents a 59.26% increase year-over-year. Quarterly sales clocked in at $55.902... 
Via Benzinga
Tempur Sealy Posts Upbeat Earnings, Joins FibroGen, Coca-Cola Consolidated, Fabrinet And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Why Zeta Global Shares Are Trading Higher By 15%; Here Are 20 Stocks Moving Premarket
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start the day with a breakdown of the biggest pre-market stock movers traders need to keep an eye on for Tuesday! 
Via InvestorPlace
FGEN Stock Earnings: FibroGen Beats EPS, Beats Revenue for Q1 2024
FGEN stock results show that FibroGen beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly... 
Via Benzinga
Exposures Glyphosate
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.